A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR (FLARE)

Centre Francois Baclesse

Status and phase: Terminated; Phase 3

Conditions: NSCLC Patients With EGFR Activating Mutation

Treatments: Drug: ERLOTINIB WITH CHEMOTHERAPY; Drug: CHEMOTHERAPY ONLY

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02178397

FLARE /GFPC 03-2013

Details and patient eligibility

About

The current first line treatment of patients with EGFR activating mutation lung cancer is EGFR TKI. Compared to platinum-based chemotherapy, EGFR-TKIs are superior in terms of response rate and progression-free survival. However, an acquired resistance occurs almost constantly. The second-line treatment includes platinum-based chemotherapy in the absence of contraindication. This chemotherapy is then administered after discontinuing EGFR TKIs.

However, a rebound phenomenon of the disease was described in patients who discontinued EGFR TKIs. Some clinical teams therefore recommend, as a precaution, in order to avoid any withdrawal phenomenon, to never discontinue EGFR TKIs in patients developing an EGFR TKI acquired resistance.

It seems therefore useful to conduct a study to better define the therapeutic strategy to adopt in patients developing an acquired resistance after having received EGFR TKIs as first line treatment.

Enrollment: 6 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Man or woman aged 18 years or more
• Non-small cell lung cancer carcinoma (NSCLC) cytologically or histologically confirmed
• Measurable disease according to RECIST 1.1 criteria
• Life expectancy greater than 12 weeks
• Performance Status (ECOG) ≤ 2
• Stage IIIB considered ineligible for thoracic radiotherapy at "curative" doses or stage IV
• Presence of at least one measurable target lesion
• Documented disease progression (RECIST 1.1) after first line treatment with erlotinib, during at least 4 months in case of partial or complete response according to RECIST criteria, or 6 months in case of stable disease. The treatment with Erlotinib should not be discontinued for more than 8 days between the progression and the inclusion in the study. The daily dose of Erlotinib should be at least 50 mg.
• Presence of one of the EGFR activating mutations in the tumor (exon 19 deletion or L858R, G719X or L861Q)
• One additional line of previous chemotherapy is allowed if administered in adjuvant or neoadjuvant setting and received more than six months before.
• Prior radiotherapy is allowed if the volume of irradiated marrow is <25% of the total bone marrow. The prior radiotherapy must be completed at least two weeks before study entry
• Brain metastases are allowed if they are controlled without steroids and if their treatment is completed (radiotherapy and/or surgery). Patients with no symptomatic brain metastases may be included; even if brain metastases are progressive and even if they are the only site of progression (since the investigator considers that irradiation is not required). These metastases have not to be life-threatening (are excluded: cerebellar metastasis ≥ 2 cm, brainstem metastasis, brain metastasis > 3 cm and/or near important functional structure).
• Normal Liver function (bilirubin ≤ULN, AST - ALT ≤2.5 x ULN, alkaline phosphatase ≤3 x ULN), or in case of liver metastases: alkaline phosphatase, AST-ALT ≤ 5 x ULN
• Normal renal function: blood creatinine ≤ULN and / or creatinine clearance> 60 ml/min calculated with the MDRD formula
• Normal blood function: absolute neutrophil count ≥ 1.5 x 109/l and / or platelets ≥ 100 x 109 / l, hemoglobin> 9 g/dl
• Woman and man under efficient contraception during treatment and at least 6 months after the end of treatment by pemetrexed or platinum or gemcitabine
• Signed written Informed consent

Exclusion criteria

• Bronchoalveolar, mixed, neuroendocrine and small cell lung cancers
• Patient with only bone metastases are not eligible
• All progressive metastatic sites treated locally (surgery, radiotherapy)
• Superior vena cava syndrome
• Uncontrolled cardiac disease requiring treatment
• Congestive heart failure, angina pectoris, significant arrhythmias or history of myocardial infarction within the previous 12 months
• Neurological or psychiatric disorders
• Uncontrolled infectious disease
• Peripheral neuropathy grade≥ 2
• Definitive contraindication for the use of steroids
• Inductive anti-epileptic treatments (phenobarbital, phenytoïne)• Previous or concomitant other cancer, including skin cancer (except basal cell cancer of the skin), except in situ treated carcinoma of the cervix , except cancer treated with surgery alone without recurrence for 5 years
• Pregnant or breastfeeding woman
• Patient follow-up not achievable
• Participation in a trial within the last 30 days
• Patient deprived of liberty as a result of a justice or administrative decision

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

6 participants in 2 patient groups

EXPERIMENTAL ARM B

Experimental group

Description:

INDUCTION chemotherapy: 4 cycles of * pemetrexed with cisplatin or carboplatin * or gemcitabine with cisplatin or carboplatin in combination with erlotinib THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed in combination with erlotinib

Treatment:

Drug: ERLOTINIB WITH CHEMOTHERAPY

STANDARD ARM A

Active Comparator group

Description:

INDUCTION chemotherapy: 4 cycles of * pemetrexed with cisplatin or carboplatin * or gemcitabine with cisplatin or carboplatin THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed

Treatment:

Drug: CHEMOTHERAPY ONLY